BioPharm

Latham BioPharm Group Continues its Expansion

Retrieved on: 
Thursday, June 17, 2021
Speidel, Consulting firm, BioPharm, Mergers and acquisitions, Information technology, Computing, Economy

BALTIMORE, June 17, 2021 /PRNewswire/ -- Latham BioPharm Group, Inc. , a leading life sciences consulting firm, recently announced some personnel changes that have taken place in alignment with the company's continued growth and development.

Key Points: 
  • BALTIMORE, June 17, 2021 /PRNewswire/ -- Latham BioPharm Group, Inc. , a leading life sciences consulting firm, recently announced some personnel changes that have taken place in alignment with the company's continued growth and development.
  • A biopharmaceutical product development professional, Dr. Speidel has broad experience that spans early development through advanced development, as well as diverse functional experience.
  • "We're delighted that Josh has accepted partnership at LBG," says Peter Latham, President and Managing Partner at LBG.
  • Strategic Consulting : full complement of capabilities supporting critical organization decision making, including market research, due diligence/M&A support and cost modeling.

Microbix & Seegene Canada Form COVID-Variant Collaboration

Retrieved on: 
Monday, March 15, 2021
BioPharm, Clinical data management, Computational biology, Distributed data storage, Information technology, Computing, Technology

MISSISSAUGA, Ontario and TORONTO, March 15, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene), a provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce a collaboration under which Seegene will distribute and recommend Microbixs new COVID-variant Quality Assessment Products (QAPs) to monitor the workflow accuracy of Seegene Allplex assays across Canada.

Key Points: 
  • MISSISSAUGA, Ontario and TORONTO, March 15, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene), a provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce a collaboration under which Seegene will distribute and recommend Microbixs new COVID-variant Quality Assessment Products (QAPs) to monitor the workflow accuracy of Seegene Allplex assays across Canada.
  • We are delighted to count Seegene Canada as a supporter of Microbix, a technical collaborator, and our latest QAPs distributor.
  • Diagnostic Intl Distribution SpA, Labquality Oy, The Medical Supply Company of Ireland Ltd, R-Biopharm AG, and Seegene Canada Inc. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.
  • Seegene Canada Inc. is a Toronto-based subsidiary of Seegene Inc. (of Seoul, Republic of Korea).

Asklepion Pharmaceuticals LLC announces AWINSA Life Sciences as its Clinical safety and Pharmacovigilance Service provider for their clinical trials in their fight against COVID-19

Retrieved on: 
Tuesday, February 9, 2021
Pharmaceuticals policy, Health, Clinical research, Clinical trials, Health care quality, Pharmacovigilance, BioPharm

PRINCETON, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AWINSA Life Sciences, a Pharmacovigilance and Clinical Safety service provider announced that it has been selected as the preferred vendor for clinical safety management by Asklepion, a biopharmaceutical company for their upcoming trials.

Key Points: 
  • PRINCETON, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AWINSA Life Sciences, a Pharmacovigilance and Clinical Safety service provider announced that it has been selected as the preferred vendor for clinical safety management by Asklepion, a biopharmaceutical company for their upcoming trials.
  • For this venture, we are excited to enter into a strategic alliance with AWINSA Life Sciences for clinical safety management, a team of intellectuals known for their proficiency in Pharmacovigilance and Clinical Safety.
  • Asklepion has taken one step forward in this direction and we feel privileged to be a part of their prestigious trials.
  • AWINSA is a service provider which provides end to end pharmacovigilance, medical information, medical writing and medical affairs services to Pharmaceutical and Biotech companies globally.

Arriello Announces Signing of First US Company to Use IntelliCASE for Clinical Pharmacovigilance Reporting

Retrieved on: 
Tuesday, January 26, 2021
Health, Pharmaceuticals policy, Clinical research, Drug Safety, Health care quality, Imetelstat, Pharmacovigilance, Telomerase, Drug Safety, BioPharm

Geron a late-stage clinical biopharmaceutical company headquartered in California, is focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Key Points: 
  • Geron a late-stage clinical biopharmaceutical company headquartered in California, is focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
  • Arriello's IntelliCASE app supports the capture of adverse event data via mobile devices, ensuring that detailed pharmacovigilance information is captured promptly and correctly.
  • With this powerful, targeted app, Arriello offers an easy to use pharmacovigilance system that's proved readily adaptable."
  • These services include market consultancy, global regulatory affairs strategy and implementation, full and local pharmacovigilance solutions, clinical drug safety and quality and compliance auditing systems.

GMAX Zhengzhou Manufacturing Site Breaks Ground

Retrieved on: 
Tuesday, December 15, 2020
Application software, BioPharm, Clinical data management, Computational biology, Distributed data storage, Software, 3D graphics software, Computing, Gmax, Hangzhou

HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.

Key Points: 
  • HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.
  • Our modern facility enables us to have direct control on product delivery," says Dr. Jing, GMAX Biopharm CEO.
  • GMAX completed phase 1b/2a trial in 2020 and plan to start phase III trial in China in 2021.
  • About Gmax Biopharm LLC: Gmax is a clinical stage company established in 2010 and headquartered in Hangzhou, China.

Pharmaceutical Technology® and BioPharm International® to Host 2020 Bio/Pharma Virtual Congress

Retrieved on: 
Thursday, October 29, 2020
Other Manufacturing, Research, Infectious diseases, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Health sciences, Pharmacy, Life sciences, Pharmaceutical sciences, Pharma, BioPharm

Pharmaceutical Technology and BioPharm International are pleased to announce their first-ever 2020 Bio/Pharma Virtual Congress, taking place Wednesday, Nov. 11, from 8:30 a.m. to 4 p.m. EST.

Key Points: 
  • Pharmaceutical Technology and BioPharm International are pleased to announce their first-ever 2020 Bio/Pharma Virtual Congress, taking place Wednesday, Nov. 11, from 8:30 a.m. to 4 p.m. EST.
  • View the full release here: https://www.businesswire.com/news/home/20201029006116/en/
    Now, more than ever, there is a need for education, as biopharmaceutical and pharmaceutical development and manufacturing have never been greater, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Pharmaceutical Technology and BioPharm International.
  • The 2020 Bio/Pharma Virtual Congress will consist of four interactive, educational tracks: formulation, manufacturing, drug dosage form trends, and bio/pharma industry challenges.
  • Pharmaceutical Technology also provides comprehensive coverage of international regulations and business trends related to drug development.

TOT BIOPHARM International Company Limited Optimises Company Management Structure to Promote Strategic Development Upgrade

Retrieved on: 
Friday, October 16, 2020
BioPharm, Clinical data management, Computational biology, Distributed data storage, TOT Public Company Limited, Information technology, Computing, Industries

HONG KONG, Oct 16, 2020 - (ACN Newswire) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), is pleased to announce that Ms. Yeh-Huang, Chun-Ying, Executive Director, has been appointed as Vice Chairman of the Board while she has resigned as General Manager of the Company.

Key Points: 
  • HONG KONG, Oct 16, 2020 - (ACN Newswire) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), is pleased to announce that Ms. Yeh-Huang, Chun-Ying, Executive Director, has been appointed as Vice Chairman of the Board while she has resigned as General Manager of the Company.
  • Mr. Fu, Shan, Chairman of the Board of the Company, said, "To implement the strategic development plan of the Company in the next decade, the appointments of the Board and the management will be conducive to optimising the Company's management structure, or initiating a long-term succession plan for the management, so that the Company will achieve long-term sustainable development and be fully equipped to enter the commercialization development stage.
  • Also, this move will enhance the development of the Company's overseas R&D projects and international cooperation projects, promoting its strategic deployment of internationalization."
  • She will also continue to promote the Company's strategic development, enhancing its brand recognition and public relations.

Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America

Retrieved on: 
Monday, September 21, 2020
Health, Clinical data management, Medical research, Articles, Clinical trial management system, Clinical research, Clinical trial, Avance, BioPharm

www.avancecro.com/eclinical-solutions

Key Points: 
  • www.avancecro.com/eclinical-solutions
    Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)
    Avance Clinical's biotech clients now have the option to deploy the latest eClinical solutions to maximise the value of study data and deliver real-time visibility on study progress.
  • Avance Clinical CEO Yvonne Lungershausen said:
    "Our Data Management team works with eClinical leaders such as Medrio to offer regulatory compliant and patient centric tools for rapid start-up and continual data flow.
  • Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
  • Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.

Enteris BioPharma to Participate in BioPharm America's Drug Delivery Partnerships 2020 Conference

Retrieved on: 
Wednesday, September 9, 2020
BioPharm, Clinical data management, Computational biology, Distributed data storage, Information technology, Computing, Industries, Draft:Sunshine Biopharma, Arbutus Biopharma

BOONTON, N.J., Sept. 9, 2020 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company is participating in the Drug Delivery Partnerships 2020 conference being hosted virtually by BioPharm America from September 21-24, 2020.

Key Points: 
  • BOONTON, N.J., Sept. 9, 2020 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company is participating in the Drug Delivery Partnerships 2020 conference being hosted virtually by BioPharm America from September 21-24, 2020.
  • Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering innovative formulation solutions utilizing its proprietary drug delivery technology, Peptelligence.
  • Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option.
  • For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com .

Samyang Biopharm USA Announces Hyun Jung Helen Lee, M.D., Named to PharmaVOICE 100

Retrieved on: 
Monday, August 3, 2020
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, BioPharm, Clinical data management, Computational biology, Distributed data storage, Samyang, Information technology, Computing, Service industries

Samyang Biopharm USA, Inc. ( https://us.samyangbiopharm.com ) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. ( https://samyangbiopharm.com/eng ), announced today that the companys President and CEO, Hyun Jung Helen Lee, M.D.

Key Points: 
  • Samyang Biopharm USA, Inc. ( https://us.samyangbiopharm.com ) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. ( https://samyangbiopharm.com/eng ), announced today that the companys President and CEO, Hyun Jung Helen Lee, M.D.
  • (Helen) has been featured in the 2020 PharmaVOICE 100, a listing of the 100 Most Inspiring People in the Life Sciences Industry.
  • The 2020 PharmaVOICE 100 honorees were selected from among thousands of nominees and are profiled in the publication's special July/August issue.
  • She has also been serving as the President of Samyang Biopharm USA Inc. since October 2018.